Q301-- Oncotype DX-Prostate (VA-21-00078881)

Agency: VETERANS AFFAIRS, DEPARTMENT OF
State: Federal
Type of Government: Federal
FSC Category:
  • Q - Medical Services
NAICS Category:
  • 621511 - Medical Laboratories
Posted Date: Aug 26, 2021
Due Date:
Solicitation No: 36C24221Q1395
Bid Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page
Follow
Q301-- Oncotype DX-Prostate (VA-21-00078881)
Active
Contract Opportunity
Notice ID
36C24221Q1395
Related Notice
Department/Ind. Agency
VETERANS AFFAIRS, DEPARTMENT OF
Sub-tier
VETERANS AFFAIRS, DEPARTMENT OF
Office
242-NETWORK CONTRACT OFFICE 02 (36C242)
General Information
  • Contract Opportunity Type: Special Notice (Original)
  • All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Original Published Date: Aug 26, 2021 12:55 pm EDT
  • Original Response Date:
  • Inactive Policy: Manual
  • Original Inactive Date: Oct 25, 2021
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
  • NAICS Code: 621511 - Medical Laboratories
  • Place of Performance:
Description
Description
Intent to Sole Source 36C24221Q1395. This is an Intent to Sole Source, this is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to provide information based on this requirement. The Department of Veterans Affairs, Network Contracting Office 2, Regional Procurement Office - East, on behalf of the James J. Peters VA Medical Center located at 130 West Kingsbridge Road Bronx, NY 10468 intends to award a Firm-Fixed-Price sole source award to GENOMIC HEALTH,INC. for Polaris test for prostate cancer risk assessment.

The contractor shall provide all resources necessary to accomplish the deliverables described in the Price / Cost Sheet listed below for the Prolaris Test for Prostate Cancer Risk Assessment at the James J. Peters VA Medical Center. The vendor shall provide all necessary shipping/transport supplies free of charge. The specimen shall be returned to the Bronx, VAMC facility, free of charge. Prolaris is a genomic test that analyzes changes in 46 genes in prostate biopsy tissue. It generates a risk score to help predict the likelihood of disease progression in men with localized prostate cancer. Prolaris is intended to guide the decision regarding active surveillance without surgery or radiation for low- or intermediate-grade cancers vs. active treatment with immediate surgery or radiation therapy.
The risk of prostate cancer progression is currently evaluated based on the prostate-specific-antigen or PSA value, the Gleason score, and clinical factors. Prolaris is intended to increase the accuracy of these risk models by adding genetic information, and it provides an estimate of prostate cancer-specific mortality risk and whether the patient s cancer is less aggressive, similarly aggressive, or more aggressive than other patients in the risk group based only on clinical factors. The genetic information alone is used to generate a 10-point score, although the final risk assessment incorporates clinical factors as well as the genetic information.

The potential clinical benefit of Prolaris is that men could make a more informed, personalized decision regarding active surveillance vs. active treatment for localized prostate cancer. This is especially relevant for patients with a low or intermediate risk of disease progression based on clinical factors as calculated by one of the risk scores mentioned earlier.
The Oncotype DX-Prostate PLA 0047U is a mRNA, gene expression profiling by real-time RT-PCR of 17 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score.

Price / Cost Sheet:

1
PROLARIS TEST FOR PROSTATE CANCER RISK ASSESSMENT
GENOMIC HEALTH, INC. is the only known vendor able to provide the above service requirement. This procurement is being conducted in accordance with FAR 8.405-6 Limited Source Justification Approval and no other vendor will satisfy agency requirements. This notice of intent is not a request for competitive quotes. No solicitation documents are available and telephone requests will not be accepted. However, any firm that believes it can meet these requirements may give written notification to the Contracting Officer by September 3, 2021 at 10:00 am EST. supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirements. Information must be sent to the Contract Specialist, Janice Brooks by email to Janice.Brooks@va.gov. Telephone requests or inquiries will not be accepted. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, NCO 2 will proceed with the sole source negotiation with GENOMIC HEALTH, INC.
All responses are due no later than 10:00 EST on September 3, 2021.
Attachments/Links
Contact Information
Contracting Office Address
  • 113 HOLLAND AVE
  • ALBANY , NY 12208
  • USA
Primary Point of Contact
Secondary Point of Contact


History
  • Aug 26, 2021 12:55 pm EDTSpecial Notice (Original)

Sign-up for a Free Trial, Government Bid Alerts

With Free Trial, you can:

You will have a full access to bids, website, and receive daily bid report via email and web.

Try One Week FREE Now

See Also

Follow Q301--Cytopathology and Thyrosequence Testing Service Active Contract Opportunity Notice ID 36C24221Q1521 Related

VETERANS AFFAIRS, DEPARTMENT OF

Follow Q301--CareDx Allosure Testing (VA-20-00099357) Active Contract Opportunity Notice ID 36C24622Q0053 Related Notice

VETERANS AFFAIRS, DEPARTMENT OF

Q522--Board Certified Therapeutic Medical Physicist Services Active Contract Opportunity 36C24821R0069 Related Notice Contract

Federal Agency

Q--621 I Professional and Allied Healthcare Staffing Services Active Contract Opportunity Notice ID

VETERANS AFFAIRS, DEPARTMENT OF

Bid Due: 10/01/2024